Pfizer’s experimental COVID-19 pill is proving effective in fighting the virus. It also appears to be effective against the Omicron variant, the company said on 14DEC. The results of its 2,250-person study show the pill's promising results: the drug reduced combined hospitalizations and deaths by about 89 per cent among high-risk adults when taken shortly after initial COVID-19 symptoms. Separate laboratory studies showed that the pill retains its potency against Omicron. The U.S.’ Food and Drug Administration is expected to soon rule whether to authorize Pfizer’s new pill, as well as a competing pill from Merck, which was submitted to regulators several weeks earlier.
You will be redirected in 2 seconds.
CLICK HERE FOR FULL STORY
